MADRIGAL PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$60.35 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-02-19
- MADRIGAL PHARMACEUTICALS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$60.35M.
- MADRIGAL PHARMACEUTICALS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$97.84M.
- MADRIGAL PHARMACEUTICALS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$78.46M.
- MADRIGAL PHARMACEUTICALS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was -$62.02M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$60.35M 10-K · filed 2026-02-19 | |
| 2024-12-31 | -$97.84M 10-K · filed 2026-02-19 | |
| 2023-12-31 | -$78.46M 10-K · filed 2026-02-19 | |
| 2022-12-31 | -$62.02M 10-K · filed 2025-02-26 | |
| 2021-12-31 | -$50.79M 10-K · filed 2024-02-28 | |
| 2020-12-31 | -$17.63M 10-K/A · filed 2023-03-03 | -$42.47M 10-K · filed 2021-02-25 |
| 2019-12-31 | -$17.63M 10-K · filed 2022-02-24 | |
| 2018-12-31 | -$6.89M 10-K · filed 2021-02-25 | |
| 2017-12-31 | -$10.59M 10-K · filed 2020-02-26 | |
| 2016-12-31 | -$8.97M 10-K · filed 2019-02-27 | |
| 2015-12-31 | -$2.34M 10-K · filed 2017-03-31 | -$23.35M 10-K · filed 2016-03-15 |
| 2014-12-31 | -$29.29M 10-K · filed 2016-03-15 | |
| 2013-12-31 | -$30.66M 10-K · filed 2016-03-15 | |
| 2012-12-31 | -$21.35M 10-K · filed 2015-03-12 | |
| 2011-12-31 | -$16.11M 10-K · filed 2014-03-11 | |
| 2010-12-31 | -$12.74M 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |